55268-75-2 Cefuroxime Acid price supplier CAS NO.55268-75-2

 Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.

Cefoxitin, the chemical name is 3-carbamoyloxymethyl-7-methoxy-7-(2-thiopheneacetamido)-8-oxo-5-thio-1-azabicyclo [4.2.0] Oct-2-ene-2-carboxylic acid, with the molecular formula C16H17N3O7S2, is a cephamycin antibiotic. It is a new type of antibiotic made by semi-synthesis of Cephamycin C produced by Streptomyces Lactamdurans. Its core is similar to cephalosporins and has similar antibacterial properties. It is customarily included in the second-generation cephalosporins. The mechanism of cefoxitin's antibacterial action is to inhibit the synthesis of the cell wall of active bacterial cells by binding to one or more penicillin binding proteins (PBPs) of bacterial cells, thereby exerting an antibacterial effect.
The antibacterial spectrum includes Escherichia coli, Pneumoniae, Indole-positive Proteus and Serratia, Klebsiella, Influenzae, Salmonella, Shigella, etc. It also has a good effect on Staphylococcus and a variety of Streptococcus. It is mainly used clinically for respiratory tract infections, endocarditis, peritonitis, pyelonephritis, urinary tract infections, sepsis and bone, joint, skin and soft tissue infections caused by sensitive bacteria.

As with the other cephalosporins, although as a second-generation variety, Cefuroxime is less susceptible to beta-lactamase. Hence, it may potentially have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae, and Lyme disease. Unlike most other second-generation cephalosporins, cefuroxime can cross the blood-brain barrier.